Understanding solvation in hydrofluoroalkanes: ab initio calculations and chemical force microscopy

Poly(amidoamine) dendrimer nanocarriers and their aerosol formulations for siRNA delivery to the lung epithelium

Small interfering RNA (siRNA)-based therapies have great promise in the treatment of a number of prevalent pulmonary disorders including lung cancer, asthma and cystic fibrosis. However, progress in this area has been hindered due to the lack of carriers that can efficiently deliver siRNA to lung epithelial cells, and also due to challenges in developing oral inhalation (OI) formulations for the regional administration of siRNA and their carriers to the lungs. In this work we report the ability of generation four, amine-terminated poly(amidoamine) (PAMAM) dendrimer (G4NH2)–siRNA complexes (dendriplexes) to silence the enhanced green fluorescent protein (eGFP) gene on A549 lung alveolar epithelial cells stably expressing eGFP. We also report the formulation of the dendriplexes and their aerosol characteristics in propellant-based portable OI devices. The size and gene silencing ability of the dendriplexes was seen not to be a strong function of the N/P ratio. Silencing efficiencies of up to 40% are reported. Stable dispersions of the dendriplexes encapsulated in mannitol and also in a biodegradable and water-soluble co-oligomer were prepared in hydrofluoroalkane (HFA)-based pressurized metered-dose inhalers (pMDIs). Their aerosol characteristics were very favorable, and conducive to deep lung deposition, with respirable fractions of up to 77%. Importantly, siRNA formulated as dendriplexes in pMDIs was shown to keep its integrity after the particle preparation processes, and also after long-term exposures to HFA. The relevance of this study stems from the fact that this is the first work to report the formulation of inhalable siRNA with aerosol properties suitable to deep lung deposition using pMDIs devices that are the least expensive and most widely used portable inhalers. This study is relevant because, also for the first time, it shows that siRNA–G4NH2 dendriplexes can efficiently target lung alveolar epithelial A549 cells and silence genes even after siRNA has been exposed to the propellant environment.

Polymeric nanocarriers for transport modulation across the pulmonary epithelium: dendrimers, polymeric nanoparticles, and their nanoblends

The purpose of this study was to (a) Determine the cellular transport and uptake of amine-terminated generation 3 (G3) poly(amido amine) (PAMAM) dendrimers across an in vitro model of the pulmonary epithelium, and the ability to modulate their transport by forming nanoblends of the dendrimers with biodegradable solid polymeric nanoparticles (NPs) and (b) to formulate dendrimer nanocarriers in portable oral inhalation devices and evaluate their aerosol characteristics. To that end, fluorescein isothiocyanate (FITC)-labeled G3 PAMAM dendrimer nanocarriers (DNCs) were synthesized, and also encapsulated within poly lactide-co-glycolide nanoparticles (NPs). Transport and uptake of both DNCs encapsulated within NPs (nanoblends) and unencapsulated DNCs were tracked across polarized monolayers of airway epithelial cells, Calu-3. DNCs were also formulated as core-shell microparticles in pressurized metered-dose inhalers (pMDIs) and their aerodynamic properties evaluated by Andersen cascade impaction. The apparent permeability of DNCs across the airway epithelial model was similar to that of a paracellular marker of comparable molar mass--order of 10(-7) cm s(-1). The transport and cellular internalization of the DNCs can be modulated by formulating them as nanoblends. The transport of the DNCs across the lung epithelium was completely suppressed within the time of the experiment (5 h) when formulated as blends. The encapsulation also prevents saturation of the cellular internalization profile. Nanoblending may be a potential strategy to modulate the rate of transport and cellular uptake of DNCs, and thus be used as a design strategy to achieve enhanced local or systemic drug delivery.

Stability and aerosolization of pressurized metered dose inhalers containing thymopentin nanoparticles produced using a bottom-up process

The objective of this study was to investigate the stability and aerosolization of pressurized metered dose inhalers (pMDIs) containing thymopentin nanoparticles. Thymopentin nanoparticles, fabricated by a bottom-up process, were suspended in hydrofluoroalkane (HFA) 134a together with cineole and/or n-heptane to produce pMDI formulations. The stability study of the pMDIs obtained was carried out at ambient temperature for 6 months. The amount of thymopentin and the aerosolization properties of pMDIs were determined using high-performance liquid chromatography (HPLC) and a twin-stage impinger (TSI), respectively. Based on the results, thymopentin nanoparticles were readily suspended in HFA 134a with the aid of cineole and/or n-heptane to form physically stable pMDI formulations, and more than 98% of the labeled amount of thymopentin and over 50% of the fine particle fraction (FPF) of the pMDIs were achieved. During storage, it was found that for all pMDIs more than 97% of the labeled amount of thymopentin and FPF greater than 47% were achieved. Moreover, the size of thymopentin nanoparticles in propellant containing cineole and n-heptane showed little change. It is, therefore, concluded that the pMDIs comprising thymopentin nanoparticles developed in this study were stable and suitable for inhalation therapy for systemic action.

Solvation in hydrofluoroalkanes: how can ethanol help?

Objectives

The goal of this work was to evaluate the ability of ethanol mixed with hydrofluoroalkanes (HFAs) to improve solvation of moieties of relevance to pressurized metered-dose inhalers (pMDIs).

Methods

Chemical force microscopy was used to measure the adhesion force (Fad) between alkyl-based, ether-based and ester-based moieties (C8/C8, COC/COC and COOC/COOC interactions) in 2H,3H-perfluoropentane (HPFP)/ethanol mixtures. HPFP is a liquid that mimics propellant HFAs. The Fad results are thus a measure of solvation in HFAs. Johnson–Kendall–Roberts (JKR) theory was used to model the results.

Key findings

The Fad normalized by the tip radius of curvature (Fad/R) decreased upon the addition of ethanol, suggesting its ability to enhance the solvent environment. At 15% (v/v) ethanol, the Fad/R was reduced 34% for the alkyl, 63% for the ether, and down 67% for the ester tails. Thus, the solvation could be ranked as: ester > ether > alkyl. JKR theory was a reasonable model for the Fad/R.

Conclusions

Ethanol, within the concentration range of interest in commercial pMDIs, provided limited enhancement in solvation of alkyl moieties. On the other hand, the cosolvent significantly enhanced solvation of ether-based and ester-based moieties, thus suggesting its potential for formulations containing amphiphiles with such groups.

Reverse aqueous microemulsions in hydrofluoroalkane propellants and their aerosol characteristics

In this work we describe the structure and environment of reverse aqueous microemulsions formed in 1,1,1,2-tetrafluoroethane (HFA134a) propellant in the presence of a non-ionic ethoxylated copolymer, and the aerosol characteristics of the corresponding pressurized metered dose inhaler (pMDI) formulations. The activity of selected polypropylene oxide-polyethylene oxide-polypropylene oxide (PO(m)EO(n)PO(m)) amphiphiles at the HFA134a-water interface was studied using in situ high-pressure tensiometry, and those results were used as a guide in the selection of the most appropriate candidate surfactant for the formation of microemulsions in the compressed HFA134a. The environment and structure of the aggregates formed with the selected surfactant candidate, PO(22)EO(14)PO(22), was probed via UV-vis spectroscopy (molecular probe), and small angle neutron scattering (SANS), respectively. High water loading capacity in the core of the nanoaggregates was achieved in the presence of ethanol. At a water-to-surfactant molar ratio of 21 and 10% ethanol, cylindrical aggregates with a radius of 18Å, and length of 254Å were confirmed with SANS. Anderson Cascade Impactor (ACI) results reveal that the concentration of the excipients (C(exp), including surfactant, water and ethanol) has a strong effect on the aerosol characteristics of the formulations, including the respirable fraction, and the mass mean aerodynamic diameter (MMAD), and that the trend in MMAD can be predicted as a function of the C(exp) following similar correlations to those proposed to common non-volatile excipients, indicating that the nanodroplets of water dispersed in the propellant behave similarly to molecularly solubilized compounds. Cytotoxicity studies of PO(22)EO(14)PO(22) were performed in A549 cells, an alveolar type II epithelial cell line, and indicate that, within the concentration range of interest, the surfactant in question decreases cell viability only lightly. The relevance of this work stems from the fact that aqueous-based HFA-pMDIs are expected to be versatile formulations, with the ability to carry a range of medically relevant hydrophilic compounds within the nanocontainers, including high potency drugs, drug combinations and biomacromolecules.

Propellant-based inhalers for the non-invasive delivery of genes via oral inhalation

In this work we describe the development of a propellant-based, portable oral inhalation platform for the pulmonary delivery of genes. A core-shell strategy is utilized to efficiently disperse cationic-polymer-DNA nanoparticles in hydrofluoroalkane propellants, and to generate aerosols from the corresponding pressurized metered-dose inhaler formulations (pMDIs) that have excellent aerosol characteristics, suitable for deep lung deposition. The engineered polyplexes and core-shell structures were fully characterized, and their ability to transfect model lung alveolar epithelium cells in vitro was demonstrated. We also show that the propellant does not affect the biological activity of the plasmid DNA, and that the core-shell formulations have no in vitro cytotoxicity. The relevance of this work stems from the fact that pMDIs are the least expensive and most widely used portable oral inhalation devices, and are thus promising platforms for targeting genes to the lungs for the treatment of medically relevant diseases including asthma, cystic fibrosis, chronic obstructive pulmonary disease, and lung cancer.

The potential for the noninvasive delivery of polymeric nanocarriers using propellant-based inhalers in the treatment of Chlamydial respiratory infections

A novel strategy for pulmonary delivery of polymeric nanocarriers (NCs) pressurized-metered dose inhalers (pMDIs) is reported in this work. Core-shell particles consisting of a water soluble, hydrofluoroalkane(HFA)-philic biodegradable copolymer of chitosan and poly(lactic acid), and a core of poly(d,l-lactide-co-glycolide) (PLGA) NCs were prepared by a modified emulsification-diffusion methodology. Dispersions of the core-shell particles in HFA propellant revealed enhanced physical stability compared to polymeric NCs alone, and more importantly, excellent aerosol characteristics as determined by inertial impaction studies. Confocal microscopy revealed that the polymeric NCs from such core-shell particles are capable not only to be taken up by Calu-3 (airway epithelial) cells that have been infected with Chlamydia pneumoniae, an intracellular pathogen, but are also internalized within chlamydial inclusions. Our results suggest that the proposed methodology can be used as a general platform for the delivery of polymeric NCs to the respiratory tract using the inexpensive pMDIs, and that such an approach may be used to target and deliver drugs to treat chlamydial-related infections.

Swellable hydrogel particles for controlled release pulmonary administration using propellant-driven metered dose inhalers

BACKGROUND

Swellable hydrogel microparticle-based pressurized metered dose inhaler (pMDI) formulations allow delivery of small respirable sized particles (1-5 microns), which swell upon the deposition in the deep lung and therefore can elude alveolar macrophage uptake via their larger geometric sizes. In addition, optimized surface chemistry may allow for sustained release of drug for multiple days.

METHODS

Drug-loaded PLGA nanoparticles encapsulated in PEG/chitosan (Cs) graft copolymer-based hydrogel microparticles were synthesized and characterized. Physical stability of dispersions within Hydrofluoroalkane propellant systems was assessed. The formulations were evaluated for aerosolization performance using a Next Generation Impactor.

RESULTS

Low density PEG/chitosan (Cs) graft copolymer-based hydrogel microparticles containing drug-loaded PLGA nanoparticles has an average diameter of 1-2 μm. These dispersions showed good compatibility with HFA227ea. Suspension stability was found to vary with the concentration of hydrogel particles. It was typically between 1 to 5 min and was found to be easily redispersible. Aerosolization studies showed fine particle fraction as high as 65% could be achieved.

CONCLUSIONS

These swellable hydrogel-based microparticle pMDI formulations could be used as potential delivery vehicles for nanoparticle therapeutics.

Reverse aqueous emulsions and microemulsions in HFA227 propellant stabilized by non-ionic ethoxylated amphiphiles

In this work we use in situ high-pressure tensiometry to screen non-ionic ethoxylated surfactants at the 1,1,1,2,3,3,3-heptafluoropropane (HFA227) propellant|Water (HFA227|W) interface. The EO(n)PO( approximately )(30)EO(n) series, where EO stands for ethylene oxide and PO for propylene oxide, and n the number of repeat EO units, was selected for this study based on the favorable interactions reported between HFA propellants and the PO moiety. The surfactants used in FDA-approved pressurized metered-dose inhaler formulations were also investigated. Tension measurements provide not only information on the relative activity of the different surfactants in the series, but they also serve as a guide for selecting an appropriate candidate for the formation of reverse aggregates based on the surfactant natural curvature. Moreover, the effect of ethanol and the chemistry of the surfactant tail group on the surfactant activity were also investigated. Surfactants with hydrogenated tails are not capable of forming stable water-in-HFA227 microemulsions. This is true even at very low tensions observed when in the presence of ethanol, indicating the lack of affinity between HFA227 and hydrogenated moieties-the surfactant does not tend to curve about water. On the other hand, PO-based amphiphiles can significantly reduce the tension of the HFA227|W interface. Small angle neutron scattering (SANS) and UV-vis spectroscopy results also reveal that a selected ethoxylated amphiphile (EO(13)PO(30)EO(13) at 1mM concentration), when in the presence of ethanol, is capable of forming stable cylindrical reverse aqueous microemulsions. EO(13)PO(30)EO(13) is also capable of forming emulsions of water-in-HFA227 that are fairly stable against coalescence. Such dispersions are potential candidates for the delivery of small polar solutes and larger therapeutic biomolecules to and through the lungs in the form of pMDI formulations, and in other medical sprays.

Solvent-solute interactions in hydrofluoroalkane propellants

Understanding solvation in hydrofluoroalkane (HFA) propellants is of great importance for the development of novel pressurized metered-dose inhaler (pMDI) formulations. HFA-based pMDIs are not only the most widely used inhalation therapy devices for delivering small drug molecules to the respiratory tract, but they also hold promise as vehicles for the delivery of therapeutic biomolecules to and through the lungs. In this work we use binding energy calculations to determine the degree of interaction between HFA propellants and candidate HFA-philes, including a methyl-based tail (isohexane, ISO), and fragments of poly(ethylene oxide) (EO), poly(propylene oxide) (PO), and poly(lactide) (LA). The distinct nature of solvation forces of the two HFA propellants approved by the FDA for use in pMDIs, 1,1,1,2-tetrafluoroethane (HFA134a) and 1,1,1,2,3,3,3-heptafluoropropane (HFA227), is also studied. Binding energy (Ebst) calculations demonstrated that an increase in tail polarity through the addition of oxygen atoms in the fragment backbone provides for sites capable of interacting with the HFA propellant molecules, thus enhancing the stabilization energy of the complexes. The interaction energy between HFA227 and LA (EbHFA227-LA = -24.7 kJ.mol(-1)) is significantly more favorable than that between HFA227 and its hydrocarbon analog (EbHFA227-ISO = -10.0 kJ.mol(-1)). However, it was shown that not only the fragment polarity is of relevance in stabilizing the complexes. The accessibility of the oxygen atoms in the fragments of interest is also relevant. Cluster studies indicate that although both oxygen atoms in the LA fragment are available to form H-bonds with the propellant molecules, the ether oxygen in PO is accessible to only one propellant molecule, thus decreasing significantly the stabilization energy of the cluster. The results shown here serve as a guide for the design of novel HFA-philes for HFA-based pMDIs.

Ethoxylated copolymersurfactants for the HFA134a- interface: interfacial activity, aggregate microstructure and biomolecule uptake

In this work we examine the aggregation behavior of ethoxylated copolymer surfactants in 1,1,1,2-tetrafluoroethane in the presence of water, and the ability of such aggregates to uptake a model biomolecule. Our approach consists of developing a rational framework for understanding the behavior of interfacially active species at the HFA134a-water (HFA134a|W) interface using a combination of in situ high-pressure tensiometry, spectroscopy, and small-angle neutron scattering (SANS). The optimum hydrophilic-to-HFA-philic balance (HFB) for the ethylene oxide-propylene oxide-ethylene oxide (EOnPO∼43EOn, where subscripts indicate the number of repeat units) surfactant series at the HFA134a|W interface was determined at 298 K and saturation pressure of the propellant (under pressure). The selection of promising candidates for the reverse aggregate formation studies was based on the tension vs. HFB scan. Tensiometric information revealed that EO3PO43EO3 occupies a very large area per molecule at the HFA134a|W interface, which represents a general trend for compressible solvents that are small and also able to interact with water more favorably than alkane solvents. The water solubilization capacity of the EO3PO43EO3 surfactant was investigated in situ by UV-vis spectroscopy, with a suitable solvatochromic probe. At a surfactant concentration above the determined critical aggregation concentration, a shift in the absorption maximum of the probe towards that of pure water was observed as the water-to-surfactant ratio increases. A similar but more pronounced shift was observed in the presence of a co-solvent. The nature of the aqueous environment associated with the aggregates is discussed based on the spectroscopic results. The microstructure of the aggregates is investigated by SANS. Scattering curves were also used to confirm the uptake of a model protein in the reverse aggregates. The relevance of this work stems from the fact that reverse aggregates of water in HFA134a are potential candidate formulations for the delivery of hydrophilic drugs, including biomolecules, to and through the lungs.

Novel propellant-driven inhalation formulations: engineering polar drug particles with surface-trapped hydrofluoroalkane-philes

Challenges in reformulating pressurized metered-dose inhalers (pMDIs) with hydrofluoroalkane (HFA) propellants, and the potential of inhalation formulations for the delivery of drugs to and through the lungs have encouraged the development of novel suspension-based pMDI formulations. In this work we propose a new methodology for engineering polar drug particles with enhanced stability and aerosol characteristics in propellant HFAs. The approach consists in 'trapping' HFA-philic moieties at the surface of particles, which are formed using a modified emulsification-diffusion method. The trapped moieties act as stabilizing agents, thus preventing flocculation of the otherwise unstable colloidal drug particles. This approach has advantages compared to surfactant-stabilized colloids in that no free stabilizers remain in solution (reduced toxicity), and the challenges associated with the synthesis of well-balanced amphiphiles are circumvented. The methodology was tested by trapping polyethylene glycol (PEG) at the surface of particles of a model polar drug-salbutamol sulfate. Colloidal probe microscopy is used to quantitatively demonstrate the trapping of the HFA-phile at the surface, and the ability of PEG in screening particle-particle cohesive interactions. Both physical stability and the corresponding aerosol characteristics are significantly improved compared to those of a commercial formulation. The fine particle fraction of PEG-coated salbutamol sulfate was observed to be 42% higher than that of Ventolin HFA. The formation of stable dispersions of terbutaline hemisulfate using the same approach, suggests this to be a generally applicable methodology to polar drugs.

Core-shell particles for the dispersion of small polar drugs and biomolecules in hydrofluoroalkane propellants

PURPOSE

Demonstrate the applicability of a novel particle-based technology for the development of suspensions of small polar drugs and biomolecules in hydrofluoroalkane (HFA) propellants for pressurized metered-dose inhalers (pMDIs).

MATERIALS AND METHODS

Emulsification diffusion was used to prepare core-shell particles. The shell consisted of oligo(lactide) grafts attached onto a short chitosan backbone. The active drug was arrested within the particle core. Colloidal Probe Microscopy (CPM) was used to determine the cohesive forces between particles in a model HFA propellant. The aerosol characteristics of the formulations were determined using an Anderson Cascade Impactor (ACI). Cytotoxicity studies were performed on lung epithelial and alveolar type II cells.

RESULTS

CPM results indicate that particle cohesive forces in liquid HFA are significantly screened in the presence of the polymeric shell and correlate well with the physical stability of suspensions in propellant HFA. The proposed formulation showed little or no cytotoxic effects on both Calu-3 and A549 cells.

CONCLUSIONS

Core-shell particles with a shell containing the lactide moiety as the HFA-phile showed excellent dispersion stability and aerosol characteristics in HFA-based pMDIs. This is a general strategy that can be used for developing novel suspension pMDIs of both small polar drugs and large therapeutic molecules.